In a ratio of research and development expenses compared with sales and marketing, drug giant GlaxoSmithKline (NYSE: GSK) skews higher on the sales side than many of its competitors.
R&D spending at the company is still hefty – more than $5.4 billion in 2015 – but sales and other general costs are also significant. Consider that R&D spending comprises about 15 percent of total revenue while selling, general and administration accounts for 39 percent of revenue.
R&D spending at the company is still hefty – more than $5.4 billion in 2015 – but sales and other general costs are also significant. Consider that R&D spending comprises about 15 percent of total revenue while selling, general and administration accounts for 39 percent of revenue.
